University of Oklahoma researchers have discovered one reason why the brain tumor glioblastoma is so aggressive.
Dxcover Limited on April 30 announced the presentation of real-world data showing a clear and consistent association between increased tumor size and mortality for patients with brain cancer.
A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped responding to chemotherapy, according to a phase III clinical trial by researchers at City of Hope.
Pfizer Inc. on April 26 announced results from the pivotal phase III CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody, in combination with standard-of-care Bacillus Calmette-Guérin as induction therapy with or without maintenance in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer.
An international clinical trial co-led by WashU Medicine found that the immunotherapy drug pembrolizumab (Keytruda) added to standard-of-care therapy improved survival for patients with locally advanced head-and-neck cancer.
Johnson & Johnson on April 26 announced new data from cohort 2 of the pivotal phase IIB SunRISe-1 study evaluating TAR-200—an intravesical gemcitabine releasing system—for patients with certain types of bladder cancer.
Zongertinib, a human epidermal growth factor receptor 2 targeted tyrosine kinase inhibitor, elicited durable responses in patients with advanced, previously treated non-small cell lung cancer that harbored a HER2 mutation, according to results from the phase IA/IB Beamion LUNG-1 trial.
The University of California Lung Cancer Consortium and AstraZeneca announced a five-year partnership to expand the Healthy Lungs California initiative, which is aimed at increasing early lung cancer detection and reducing deaths from the disease.
A team of researchers from the Keck School of Medicine of USC has developed an advanced tool for analyzing chimeric antigen receptor T cells, including how they evolve during manufacturing and which ones are most effective at killing cancer.
Researchers at the University of California San Diego School of Medicine have found that individuals with colon cancer and a documented history of high cannabis use were more than 20 times more likely to die within five years of diagnosis compared to those without such a history.
